MEG3 and lung adenocarcinoma: Indeed, earlier investigations in lung adenocarcinoma showed that MEG3 overexpression enhanced cisplatin sensitivity through p53-dependent regulation and downregulation of Bcl-XL, supporting the idea that MEG3's apoptotic regulation may vary across tumor contexts but is consistently associated with improved drug responsiveness (Zhang et al., 2023).